Cargando…

Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis

BACKGROUND: Patients with atrial fibrillation (AF) and frailty are a considerable group in clinical practice. However, existing studies provide insufficient evidence of anticoagulation strategies for these patients. Therefore, we conducted a meta-analysis to determine the effectiveness and safety ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Shan, Zheng, Yuxiang, Jiang, Jingzhou, Ma, Jianyong, Zhu, Wengen, Cai, Xingming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263568/ https://www.ncbi.nlm.nih.gov/pubmed/35811719 http://dx.doi.org/10.3389/fcvm.2022.907197

Ejemplares similares

Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Gao, Xinxing, et al.
Publicado: (2021)

An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve
por: Cao, Yalin, et al.
Publicado: (2022)

Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies
por: Liu, Fuwei, et al.
Publicado: (2021)

Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?
por: Hardy, Michael, et al.
Publicado: (2022)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four post-hoc Analyses of Randomized Clinical Trials
por: Liu, Fuwei, et al.
Publicado: (2022)

Is the Risk of Diabetes Lower in Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulant Compared to Warfarin?
por: Liu, Xuyang, et al.
Publicado: (2022)

Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
por: Wang, Chun-Li, et al.
Publicado: (2021)

Editorial: Effects of oral anticoagulant therapy in atrial fibrillation patients with comorbidities
por: Li, Runkai, et al.
Publicado: (2023)

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization
por: Yu, Qingyuan, et al.
Publicado: (2022)

Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2022)

Direct Oral Anticoagulants vs. Warfarin in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Elfar, Sohil, et al.
Publicado: (2022)

Reappraisal of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2021)

Impact of COPD or Asthma on the Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Xue, Zhengbiao, et al.
Publicado: (2022)

Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
por: Choi, Ju Hee, et al.
Publicado: (2022)

Association of Coffee Consumption With Atrial Fibrillation Risk: An Updated Dose–Response Meta-Analysis of Prospective Studies
por: Cao, Yalin, et al.
Publicado: (2022)

Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis
por: Li, Zuwei, et al.
Publicado: (2021)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Associations of Antidepressants With Atrial Fibrillation and Ventricular Arrhythmias: A Systematic Review and Meta-Analysis
por: Cao, Yalin, et al.
Publicado: (2022)

The “Obesity Paradox” in Patients With HFpEF With or Without Comorbid Atrial Fibrillation
por: Guo, Linjuan, et al.
Publicado: (2022)

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes
por: Gallagher, Arlene M, et al.
Publicado: (2014)

Association of Depression, Antidepressants With Atrial Fibrillation Risk: A Systemic Review and Meta-Analysis
por: Fu, Yonghui, et al.
Publicado: (2022)

Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol
por: Li, Guowei, et al.
Publicado: (2015)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
por: Lin, Dong, et al.
Publicado: (2021)

Comparison of effectiveness and safety of high-power vs. conventional-power radiofrequency ablation for treatment of atrial fibrillation
por: Cui, Penghui, et al.
Publicado: (2022)

Hyperuricemia Is Associated With the Risk of Atrial Fibrillation Independent of Sex: A Dose-Response Meta-Analysis
por: Xiong, Jianhua, et al.
Publicado: (2022)

Sex-Specific Exposure–Effect Relationship Between Physical Activity and Incident Atrial Fibrillation in the General Population: A Dose–Response Meta-Analysis of 16 Prospective Studies
por: Wan, Qin, et al.
Publicado: (2021)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Association Between the Frailty and New-Onset Atrial Fibrillation/Flutter Among Elderly Hypertensive Patients
por: Hang, Fei, et al.
Publicado: (2022)

Renal outcomes of rivaroxaban compared with warfarin in Asian patients with nonvalvular atrial fibrillation: A nationwide population-based cohort study
por: Lee, So-Ryoung, et al.
Publicado: (2023)

Combined atrial fibrillation ablation and left atrial appendage closure: Watchman vs. LAmbre devices
por: Ke, Jin-Yan, et al.
Publicado: (2022)

Associations of body mass index with mortality in heart failure with preserved ejection fraction patients with ischemic versus non-ischemic etiology
por: Zeng, Shan, et al.
Publicado: (2022)

Comparison of the Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Bitar, Yasmin de Souza Lima, et al.
Publicado: (2021)

Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care
por: González-Pérez, Antonio, et al.
Publicado: (2022)

Associations of anaemia with bleeding and thrombotic complications in patients with atrial fibrillation treated with warfarin: a registry-based nested case–control study
por: Helin, Tuukka Antero, et al.
Publicado: (2023)

Early rhythm control vs. rate control in atrial fibrillation: A systematic review and meta-analysis
por: Han, Shaojie, et al.
Publicado: (2023)

Outcomes of catheter ablation vs. medical treatment for atrial fibrillation and heart failure: a meta-analysis
por: Lee, Wei-Chieh, et al.
Publicado: (2023)

Impact of frailty on early rhythm control outcomes in older adults with atrial fibrillation: A nationwide cohort study
por: Yu, Ga-In, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7jki8qvicg4g5bj0t7vaejuhap